Solstice Neurosciences Inc

Type: Company
Name: Solstice Neurosciences Inc
Nationality: United States
Web Address:
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Cipher Pharmaceuticals appoints Shawn Patrick O'Brien as CEO

Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, June 26, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien has been appointed Chief Executive Officer of Cipher, effective June ... [Published - Jun 26 2014]


...very pleased to welcome a high-caliber executive like Shawn to lead the next phase of growth for the Company," said Gerry McDole, Chair of Cipher. "Shawn has a very unique background, including a proven track record with commercial-stage companies in Canada and the U S and a blend of business development, sales & marketing, regulatory and R&D experience. His background aligns very well with Cipher's core capabilities and growth aspirations." compared to botulinum toxin type A (and thus the routine use of many thousands of units of botulinum toxin type B, as known in the art, see e g. "Long-term safety, efficacy, and dosing of botulinum toxin type B (MYOBLOC.RTM.) in cervical dystonia (CD) and other movement disorders" Kumar R and Seeberger L C Mov Disord 2002; 17(Suppl 5):S292-S293)...

More Content

All (2) | News (2) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Cipher Pharmaceuticals appoints Shawn Patrick O... [Published - Jun 26 2014]
Suture line administration technique using botu... [Published PharmCast - Jan 15 2014]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.